New antiarrhythmic drug in pediatric use: Sotalol

Pediatric Cardiology

Volumn 18, Issue 1, 1997, Pages 28-34

  Pfammatter, J P ^a   Paul, T ^b  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Electrophysiology; Pharmacokinetics; Proarrhythmia; Side effects; Sotalol

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NEW DRUG; SOTALOL;

ANTIARRHYTHMIC ACTIVITY; ARRHYTHMOGENESIS; ARTICLE; ATRIOVENTRICULAR BLOCK; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CHILD; DRUG EFFICACY; ELECTROCARDIOGRAPHY MONITORING; FATIGUE; HEART ARRHYTHMIA; HEART ATRIUM FLUTTER; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; REENTRY TACHYCARDIA; SUPRAVENTRICULAR TACHYCARDIA; VERTIGO;

ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; CHILD; CHILD, PRESCHOOL; ELECTROPHYSIOLOGY; HUMANS; SOTALOL;

EID: 0031060577     PISSN: 01720643     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002469900104     Document Type: Article

References (62)

1. Aberg G, Dzedin T, Lundholm L, Olsson L, Svedmyr N (1969) A comparative study of some cardiovascular effects of sotalol and propranolol. Life Sci 5:353-365
2. Anastasiou-Nana MI, Gilbert EM, Miller RH, Singh S, Freedman RA (1991) Usefulness of d,1-sotalol for suppression of chronic ventricular arrhythmias. Am J Cardiol 67:511-516
3. Anderson JL (1990) Effectiveness of sotalol for therapy of complex ventricular arrhythmias and comparison with placebo and class I antiarrhythmic drugs. Am J Cardiol 65:37A-42A
4. Antonaccio MJ, Gomoll A (1993) Pharmacologic basis of the antiarrhythmic and hemodynamic effects of sotalol. Am J Cardiol 72:27A-37A
5. Arendt RM, Greenblatt DJ, de Jong RH (1984) Pharmacokinetics, central nervous system uptake and lipid solubility of propranolol, acebutolol and sotalol. Cardiology 71:307-314
6. Berglund G, Descamps R, Thomis JA (1989) Pharmacokinetics of sotalol after chronic administration to patients with renal insufficiency. Eur J Clin Pharmacol Ther 18:321-326
7. Blair AD, Burgess ED, Maxwell BM (1981) Sotalol kinetics in renal insufficiency. Clin Pharmacol Ther 29:457-463
8. Blinks JR (1967) Evaluation of the cardiac effects of several beta- adrenergic blocking agents. Ann NY Acad Sci 139:673-685
9. Cumm AJ, Paul V (1990) Sotalol for paroxysmal supraventricular tachycardias. Am J Cardiol 65:67A-73A
10. Campbell TJ, Gavaghan TP, Morgan JJ (1985) Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Br Heart J 54:86-90
11. Curmeliet E (1985) Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. J Pharmacol Exp Ther 232:817-825
12. Claudel JP, Touboul P (1995) Sotalol: from "just another beta-blocker" to the prototype of class III antiarrhythmic compounds. PACE 18:451-467
13. Colloridi V, Perri C, Ventriglia F, Critelli G (1992) Oral sotalol in pediatric atrial ectopic tachycardia. Am Heart J 123:254-256
14. Dumas M, d'Athis P, Besancenot JF (1989) Variations of sotalol kinetics in renal insufficiency. Int J Clin Pharmacol Ther Toxicol 27:468-489
15. El Sherif N, Zeiler RH, Craelius W, Gough WB, Henkin R (1988) QTU prolongation and polymorphic ventricular tachyarrhythmias due to bradycardia dependent early after-depolarizations. Circ Res 63:286-305
16. Fish FA, Gillette PC, Benson WD (1991) Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. J Am Coll Cardiol 18:356-365
17. Freedman RA, Karagounis LA, Steinberg JS (1992) Effects of sotalol on the signal-averaged electrocardiogram in patients with sustained ventricular tachycardia: relation to suppression of inducibility and changes in tachycardia cycle length. J Am Coll Cardiol 20:1213-1219
18. Garson A (1990) Ventricular arrhythmias. In: Garson A, Gillette PC (eds) Pediatric Cardiac Dysrhythmias: Electrophysiology and Pacing. Saunders, Philadelphia, pp 487-490
19. Gomoll AW, Braunwald E (1973) Comparative effects of sotalol and propranolol on myocardial contractility. Arch Int Pharmacodyn Ther 205:338-354
20. Gonzalez R, Scheinman MM, Herre JM, et al (1988) Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias. J Am Coll Cardiol 12:1568-1572
21. Groh WJ, Gibson KJ, McAnulty JH, Maylic JG (1995) Beta-adrenergic blocking property of dl-sotalol maintains class III efficacy in guinea pig ventricular muscle after isoproterenol. Circulation 91:262-264
22. Hackett LP, Wojnar-Horton RE, Dusci LJ (1990) Excretion of sotalol in breast milk. Br J Clin Pharmacol 29:277-278
23. Hanyok JJ (1993) Clinical pharmacokinetics of sotalol. Am J Cardiol 72:19A-26A
24. Ho DSW, Cooper MJ, Richards DAB, Uther JB, Ross DL (1995) Rapid intravenous infusion of d,1-sotalol: time to onset of effects on ventricular refractoriness and safety. Eur Heart J 16:81-86
25. Hohnloser SH, Arendts W, Quart B (1992) Incidence, type and dose-dependence of proarrhythmic events during sotalol therapy in patients treated for sustained ventricular tachycardia. PACE 15:551 [abstract]
26. Hohnloser SH, van de Loo A, Kalusche D, Arendts W, Quart B (1993) Does sotalol-induced alteration of QT dispersion predict drug effectiveness or proarrhythmic hazards? Circulation 88 (Suppl I):397
27. Hosking M, Hamilton R, Gow R, Freedom R (1990) Efficacy and side effects of oral sotalol in children. PACE 13:541 [abstract]
28. Houyel L, Fournier A, Ducharme C, Chartrand C, Davignon A (1992) Electrophysiologic effects of sotalol on the immature mammalian heart. J Cardiovasc Pharmacol 19:134-139
29. Jordaens L, Gorgels A, Stroobandt R, Temmerman J (1991) Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia. Am J Cardiol 68:35-40
30. Kato R, Ikeda N, Yabek SM, Kannan R, Singh BN (1986) Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics. J Am Coll Cardiol 7:116-125
31. Kauman AJ, Aramendia P (1968) Prevention of ventricular fibrillation induced by coronary ligation. J Pharmacol Exp Ther 164:326-332
32. Kehoe RF, Zheutlin TA, Dunnington CS, et al (1990) Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias. Am J Cardiol 65:58A-64A
33. Khan MI, Hamilton JT, Manning GW (1972) Protective effect of beta adrenoceptor blockade in experimental coronary occlusion in conscious dogs. Am J Cardiol 30:832-837
34. Klein RC, ESVEM Investigators (1993) Comparative efficacy of sotalol and class I antiarrhythmic agents in patients with ventricular tachycardia or fibrillation: results of the ESVEM trial. Eur Heart J 14 (Suppl H):78-84
35. Koike K, Hesslein PS, Finlay CD, et al (1988) Atrial automatic tachycardia in children. Am J Cardiol 61:1127-1130
36. Kunze KP, Schlüter M, Kuck KH (1987) Sotalol in patients with Wolff-Parkinson-White syndrome. Circulation 75:1050-1057
37. Kus T, Campa MA, Nadeau R, et al (1992) Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease. Am Heart J 123:82-88
38. Lathrop DA, Varro A (1990) The combined electrophysiological effects of lignocaine and sotalol in canine isolated Purkinje fibers are rate-dependent. Br J Pharmacol 99:124-130
39. MacNeil DJ, Davies RO, Deitchman D (1993) Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol 72: 44A-50A
40. Manz M, Kuhl AJ, Lüderitz B (1985) Sotalol bei supraventrikulärer Tachykardie: Elektrophysiologische Messungen bei Wolff-Parkinson-White Syndrom und AV-Knoten-Reentrytachykardie. Z Kardiol 74:500-505
41. Maragnes P, Tipple M, Fournier A (1992) Effectiveness of oral sotalol for treatment of pediatric arrhythmias. Am J Cardiol 69: 751-754
42. Meden H, Neeb U (1990) Transplazentare Konversion bei fetaler supraventrikulärer Tachykardie mit Sotalol. Z Geburtshilfe Perinatol 194:182-184
43. Moak JP (1990) Developmental cellular electrophysiologic effects of d-sotalol on canine cardiac Purkinje fibers. Pediatr Res 29:104- 109
44. Morganroth J (1988) Evaluation of antiarrhythmic therapy using Holter monitoring. Am J Cardiol 62:18H-23H
45. Nademanee K, Singh BN (1990) Effects of sotalol on ventricular tachycardia and fibrillation produced by programmed electrical stimulation: comparison with other antiarrhythmic agents. Am J Cardiol 65:53A-57A
46. Nakaya H, Kimura S, Nakao Y, Kanno M (1984) Effects of nipradilol on the electrophysiological properties of canine cardiac tissues: comparison with propranolol and sotalol. Eur J Pharmacol 104:335-344
47. Paul T, Lehmann C, Pfammatter JP, Kallfelz HC (1994) Ergebnisse der oralen Sotaloltherapie bei Kindern mit supraventrikulären und ventrikulären Dysrhythmien. Z Kardiol 83:891-897
48. Pfammatter JP, Paul T, Lehmann C, Kallfelz HC (1995) Efficacy and proarrhythmia of oral sotalol in pediatric patients. J Am Coll Cardiol 26:1002-1007
49. Roden DM (1994) Risks and benefits of antiarrhythmic therapy. N Engl J Med 331:785-791
50. Schnelle K, Klein G, Schinz A (1979) Studies on the pharmacokinetics and pharmacodynamics of the beta-adrenergic blocking agent sotalol in normal man. J Clin Pharmacol 9:1516-1522
51. Singh BN (1989) When is QT prolongation antiarrhythmic and when is it proarrhythmic? Am J Cardiol 63:867-869
52. Singh BN (1990) Historical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: particular reference to sotalol. Am J Cardiol 65 (Suppl):3A-11A
53. Singh BN, Vaughan Williams EM (1970) A third class of antiarrhythmic action: effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle of MJ 1999 and AH 3676. Br J Pharmacol 39:675-689
54. Soyka LF, Wirtz C, Sprangenberg (1990) Clinical safety profile in patients with arrhythmias. Am J Cardiol 65:74A-81A
55. Strauss HC, Bigger JT, Hoffman BF (1970) Electrophysiological and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue. Circ Res 26:661-670
56. Sundquist H (1980) Basic review and comparison of beta-blocker pharmacokinetics. Curr Ther Res 28:38S-44S
57. Teo KK, Harte MB, Horgan JH (1985) Sotalol infusion in the treatment of supraventricular tachyarrhythmias. Chest 87:113-118
58. Tipple M, Sandor G (1991) Efficacy and safety of oral sotalol in early infancy. PACE 14:2062-2065
59. Tjandramaga TB, Thomas J, Verbeeck R, et al (1976) The effect of end-stage renal failure and hemodialysis on the elimination kinetics of sotalol. Br J Clin Pharmacol 3:259-265
60. Velebit V, Podrid P, Lown B, Cohen BH, Graboys TB (1982) Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 65:886-894
61. Woosley RL, Barbey JT, Wang T (1990) Concentration/response relations for the multiple antiarrhythmic actions of sotalol. Am J Cardiol 65 (Suppl):12A-21A
62. Zabel M, Portnoy S, Franz MR (1995) Electrocardiographic indexes of dispersion of ventricular repolarization: an isolated heart validation study. J Am Coll Cardiol 25:746-752